Hodgkin lymphoma: Pathology, pathogenesis, and a plethora of potential prognostic predictors

Advances in Anatomic Pathology

Volumn 21, Issue 1, 2014, Pages 12-25

  King, Rebecca L ^a,b   Howard, Matthew T ^c   Bagg, Adam ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Classical Hodgkin lymphoma; Genetics; Hodgkin lymphoma; Nodular lymphocyte predominant Hodgkin lymphoma; Prognosis

Indexed keywords

B LYMPHOCYTE; CANCER GENETICS; CANCER PROGNOSIS; CANCER THERAPY; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EPSTEIN BARR VIRUS; GRAY ZONE LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; INFLAMMATORY CELL; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PATHOGENESIS; PATHOLOGIST; PRIORITY JOURNAL; REVIEW;

HODGKIN DISEASE; HUMANS; PROGNOSIS;

EID: 84890513409     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000002     Document Type: Review

References (115)

1. Hodgkin T. On some morbid appearances of the assorbant glands and spleen. Med Chir Trans. 1832;17: 69-97.
2. Reed D. On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10: 133-196.
3. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 1994;91: 10962-10966.
4. Kuppers R, Kanzler H, Hansmann ML, et al. Single cell analysis of Hodgkin/Reed-Sternberg cells. Ann Oncol. 1996; 7(suppl 4): 27-30.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013;CA. Cancer J Clin. 2013;63: 11-30.
6. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
7. Glaser SL, Jarrett RF. The epidemiology of Hodgkin's disease. Baillieres Clin Haematol. 1996;9: 401-416. (Pubitemid 26362737)
8. Gutensohn N, Cole P. Epidemiology of Hodgkin's disease. Semin Oncol. 1980;7: 92-102. (Pubitemid 10002261)
9. MacMahon B. The epidemiology of Hodgkin's disease. Cancer Res. 1966;26: 1189-1200.
10. Kaplan H. Hodgkin's disease: biology, treatment, prognosis. Blood. 1981;57: 813-822. (Pubitemid 11096469)
11. Kaplan HS. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer. 1980; 45: 2439-2474. (Pubitemid 10105298)
12. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87: 1096-1103.
13. Diehl V, Sextro M, Franklin J, et al. Clinical Presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17: 776-783. (Pubitemid 29109305)
14. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011; 29: 1812-1826.
15. Bagg A, Roullet MR, Watt C. Application of molecular genetics to the diagnosis and classification of hematopoietic neoplasms. In: Knowles D, ed. Neoplastic Hematopathology. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2013: 194-231.
16. Koh YW, Park C, Yoon DH, et al. Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma. Am J Surg Pathol. 2013;37: 1242-1251.
17. Gratzinger D. VEGF, the salt in the Hodgkin cytokine stew? Leuk Lymphoma. 2013. [Epub ahed of print].
18. Roullet MR, Bagg A. Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed- Sternberg cell. Expert Rev Mol Diagn. 2007;7: 805-820. (Pubitemid 350171843)
19. Diehl V, Klimm B, Re D. Hodgkin lymphoma: a curable disease: what comes next? Eur J Haematol Suppl. 2005;66: 6-13. (Pubitemid 40873972)
20. Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988- 1998. Cancer. 2003;98: 300-309. (Pubitemid 36828454)
21. Kanzler H, Kuppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184: 1495-1505. (Pubitemid 26354704)
22. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reedsternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95: 1443-1450. (Pubitemid 30099859)
23. Steidl C, Shah SP, Woolcock BW. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471: 377-381.
24. Tang H, Wei Q, Ge J, et al. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma. Hum Pathol. 2013;44: 2167-2172.
25. King RL, Pasha T, Roullet MR, et al. IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Hum Pathol. 2009;40: 1699-1705.
26. Natkunam Y, Hsi ED, Aoun P, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. Blood. 2007;109: 298-305. (Pubitemid 46053070)
27. Shams TM. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas. J Egypt Natl Canc Inst. 2011;23: 147-153.
28. Buettner M, Greiner A, Avramidou A, et al. Evidence of abortive plasma cell differentiation in Hodgkin and Reed- Sternberg cells of classical Hodgkin lymphoma. Hematol Oncol. 2005;23: 127-132. (Pubitemid 43061890)
29. Bhargava P, Pantanowitz L, Pinkus GS, et al. Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2009;18: 16-23.
30. Fan Z, Natkunam Y, Bair E. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27: 1346-1356. (Pubitemid 37185826)
31. Harris NL. Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications. Mod Pathol. 2013;26:S57-S70.
32. Sundeen J, Cossman J, Jaffe E. Lymphocyte predominant Hodgkin's disease nodular subtype with coexistent "large cell lymphoma." Histological progression or composite malignancy? Am J Surg Pathol. 1988;12: 599-606.
33. Hansmann ML, Stein H, Fellbaum C, et al. Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol. 1989;20: 1169-1175. (Pubitemid 20034146)
34. Greiner T, Gascoyne R, Anderson M, et al. Nodular lymphocyte-predominant Hodgkin's disease associated with large- cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood. 1996;88: 657-666. (Pubitemid 26240397)
35. Cotta CV, Coleman JF, Li S, et al. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site. Histopathology. 2011;59: 1194-1203.
36. McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol. 2006;19: 1010-1018.
37. Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205: 2251-2268.
38. Eberle FC, Rodriguez-Canales J, Wei L. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96: 558-566.
39. Grant C, Dunleavy K, Eberle FC. Primary mediastinal large Bcell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6: 157-163.
40. Martelli M, Ferreri AJ, Johnson P. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2008;68: 256-263.
41. Oschlies I, Burkhardt B, Salaverria I. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96: 262-268.
42. Rosenwald A, Wright G, Leroy K. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198: 851-862. (Pubitemid 37152922)
43. Savage KJ, Monti S, Kutok JL. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102: 3871-3879. (Pubitemid 37486965)
44. Traverse-Glehen A, Pittaluga S, Gaulard P. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29: 1411-1421. (Pubitemid 41513290)
45. Iochim HL, Medeiros LJ. Iochim's Lymph Node Pathology. Philadelphia: Lippincott Williams & Wilkins; 2009.
46. Hansmann ML, Fellbaum C, Hui P, et al. Progressive transformation of germinal centers with and without association to Hodgkin's disease. Am J Clin Pathol. 1990;93: 219-226. (Pubitemid 20068424)
47. Jaffe ES, Harris NL, Vardiman JW, et al. Hematopathology. Philadelphia: Elsevier Saunders; 2011.
48. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10: 589-597.
49. Zelenetz AD, Advani RH, Buadi F, et al. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4: 258-310. (Pubitemid 44274817)
50. Boudová L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102: 3753-3758. (Pubitemid 37409397)
51. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60: 549-552. (Pubitemid 30094549)
52. Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99: 1381-1387. (Pubitemid 34547095)
53. Kupper M, Joos S, von Bonin F, et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol. 2001;112: 768-775. (Pubitemid 32222851)
54. Steidl C, Diepstra A, Lee T, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012;120: 3530-3540.
55. Steidl C, Telenius A, Shah SP, et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood. 2010;116: 418-427.
56. Choi JH, Li Y, Guo J, et al. Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylationenriched bisulfite sequencing. PLoS One. 2010;5:e13020.
57. Weniger MA, Barth TF, Moller P. Genomic alterations in Hodgkin's lymphoma. Int J Hematol. 2006;83: 379-384. (Pubitemid 44756786)
58. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Investig. 1997;100: 2961-2969. (Pubitemid 28022832)
59. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed- Sternberg cells. Blood. 1999;94: 3129-3134. (Pubitemid 29512720)
60. Emmerich F, Theurich S, Hummel M, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol. 2003;201: 413-420. (Pubitemid 37408262)
61. Eckerle S, Brune V, Doring C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia. 2009;23: 2129-2138.
62. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206: 981-989.
63. Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99: 3398-3403. (Pubitemid 34525322)
64. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003;102: 1019-1027. (Pubitemid 36917799)
65. Van Roosbroeck K, Cox L, Tousseyn T, et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood. 2011; 117: 4056-4064.
66. Weniger MA, Melzner I, Menz CK, et al. [Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho- STAT5 accumulation]. Verh Dtsch Ges Pathol. 2006;90: 210-215.
67. Schumacher MA, Schmitz R, Brune V, et al. Mutations in the genes coding for the NF-kB regulating factors IkBa and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. Haematologica. 2010;95: 153-157.
68. Kapatai G, Murray P. Contribution of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol. 2007;60: 1342-1349. (Pubitemid 350252944)
69. Schwering I, Brauninger A, Klein U, et al. Loss of the Blineage- specific gene expression program in Hodgkin and reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101: 1505-1512. (Pubitemid 36182527)
70. Tiacci E, Döring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 2012;120: 4609-4620.
71. Ushmorov A, Leithäuser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107: 2493-2500. (Pubitemid 43345573)
72. Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010;24: 233-238.
73. Lowry L, Hoskin P, Linch D. Developments in the management of Hodgkin's lymphoma. Lancet. 2010;375: 786-788.
74. Aleman B, van den Belt-Dusebout A, Klokman W, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21: 3431-3439. (Pubitemid 46603515)
75. Navarro A, Diaz T, Martinez A, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114: 2945-2951.
76. Greaves W, Xiao L, Sanchez-Espiridion B, et al. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol. 2012;5: 47-52.
77. Tiacci E, Doring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 2012;120: 4609-4620.
78. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood. 2003;101: 706-710. (Pubitemid 36077597)
79. Stamatoullas A, Picquenot JM, Dumesnil C, et al. Conventional cytogenetics of nodular lymphocyte-predominant Hodgkin's lymphoma. Leukemia. 2007;21: 2064-2067. (Pubitemid 47299990)
80. Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood. 2006;108: 1013-1020. (Pubitemid 44154639)
81. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virusassociated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70: 375-382. (Pubitemid 27107262)
82. Bräuninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer. 2006;118: 1853-1861.
83. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer. 1999; 84: 442-448. (Pubitemid 29337135)
84. Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013;121: 3547-3553.
85. Hasenclever D, Diehl V, Armitage JO, et al. Prognostic Score for advanced Hodgkin's disease. N Engl J Med. 1998;339: 1506-1514. (Pubitemid 28543499)
86. Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120: 3280-3287.
87. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362: 875-885.
88. Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012;97: 262-269.
89. Porrata LF, Ristow K, Habermann TM, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012;157: 321-330.
90. Koh YW, Kang HJ, Park C, et al. Prognostic Significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic hodgkin lymphoma. Am J Clin Pathol. 2012; 138: 846-854.
91. Canioni D, Deau-Fischer B, Taupin P, et al. Prognostic significance of new immunohistochemical markers in refractory classical hodgkin lymphoma: a study of 59 cases. PLoS One. 2009;4:e6341.
92. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100: 3935-3941. (Pubitemid 35396858)
93. Sup SJ, Alemany CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol. 2005;23: 3773-3779.
94. Venkataraman G, Song JY, Tzankov A, et al. Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. Blood. 2013;121: 1795-1804.
95. Kamper P, Ludvigsen M, Bendix K, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/ refractory disease in classical Hodgkin lymphoma. Blood. 2011;117: 6638-6649.
96. Ouyang J, Plütschow A, Pogge von Strandmann E, et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood. 2013; 121: 3431-3433.
97. Scott DW, Chan FC, Hong F, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 2012;31: 692-700.
98. Sánchez-Espiridión B, Martín-Moreno AM, Montalbán C, et al. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol. 2013;162: 336-347.
99. Harris J, Jain S, Ren Q, et al. CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma. Diagn Pathol. 2012;7:12.
100. Azambuja D. Lack of association of tumor associated macrophages with clinical outcome in patients with classical Hogkin's lymphoma. Ann Oncol. 2011;23: 736-742.
101. Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica. 2012;97: 1080-1084.
102. Sanchez-Aguilera A. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108: 662-668. (Pubitemid 44061368)
103. Steidl C. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362: 875-885.
104. Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004;125: 701-708. (Pubitemid 38813596)
105. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20: 1278-1287. (Pubitemid 34177434)
106. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379: 1791-1799.
107. Küppers R, Engert A, Hansmann M-L. Hodgkin lymphoma. J Clin Investig. 2012;122: 3439-3447.
108. Xing KH, Savage KJ. Modern management of lymphocyte predominant Hodgkin lymphoma. Br J Haematol. 2013;161: 316-329.
109. Hsi E. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphom. 2008;49: 1668-1680.
110. Diepstra A, van Imhoff G, Karim-Kos H, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol. 2007;25: 3101-3108. (Pubitemid 47218058)
111. Sup S, Alemany C, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol. 2005;23: 3773-3779.
112. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368: 1509-1518.
113. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365: 725-733.
114. Rassidakis G, Medeiros L, Vassilakopoulos T, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100: 3935-3941. (Pubitemid 35396858)
115. Hsi E, Sup S, Alemany C, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol. 2006;125: 776-782.